NCT02794805已完成2 期
Evaluation of the Capability of the ¹³C-Octanoate Breath Test (OBT) Measurement to Differentiate Between Presence and Absence of HCC Determined by MRI in Patients With Chronic Liver Disease
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 74
- 试验地点
- 4
- 主要终点
- 13CO2/12CO2 ratio
研究概览
简要总结
An Octanoate breath test will be used to assess the presence of Hepatocellular Carcinoma in subjects with risk. The gold standard will be MRI.
详细描述
- Informed consent will be obtained from all patients prior to enrollment.
- The trial will be conducted in compliance with this protocol, with GCP standards, and the applicable regulatory requirements.
- This study will be cross-sectional, where patients will be enrolled on a walk in basis. Once one arm is completed the other one will be enriched in order to obtain at least 50 positive and at least 50 negative HCC subjects as defined by MRI.
- All patients will undergo AFP and US if they do not have results within the past three months.
- If the patient undergoes liver FNA, the biopsy results will be evaluated for the presence of HCC.
- For all patients, a case report form will be completed.
- All patients will undergo a physical examination, and their medical history/concomitant medications, weight, height and age will be recorded. Furthermore, recent (past 3 months) blood test results, if available, may be recorded.
- If relevant (woman of child bearing age), a pregnancy test will be performed to rule out pregnancy when performing the breath test.
- All MRI negative patients with low OBT results will undergo additional MRI within 6 to 12 months post OBT to rule out HCC occurrence.
- If available, all additional MRI/CT/US results will be recorded within the patient's CRF.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- Single (Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Any patients with chronic liver disease at risk for HCC.
- •Age ≥ 18 years.
- •Patient has an MRI result (positive or negative for HCC) up to 3 months prior to recruitment or will be scheduled for an MRI during the trial period.
- •Patient is naïve to HCC treatment (RFA or TACE or Oral HCC treatments) since last MRI.
排除标准
- •Any patients with chronic liver disease at risk for HCC.
- •Age ≥ 18 years.
- •Patient has an MRI result (positive or negative for HCC) up to 3 months prior to recruitment or will be scheduled for an MRI during the trial period.
- •Patient is naïve to HCC treatment (RFA or TACE or Oral HCC treatments) since last MRI.
- •Patients currently receiving total parenteral nutrition if they have contraindications to oral drugs.
- •Women who are pregnant or breast feeding.
- •Patient taking drugs that can interfere with octanoate metabolism or can also cause NAFLD independent of the metabolic syndrome, including: corticosteroids, amiodarone, tetracycline, valproic acid, methotrexate, stavudine, zidovudine.
- •Patient, based on the opinion of the investigator, should not be enrolled into this study.
- •Patient unable or unwilling to sign informed consent.
- •Patients that are participating in other clinical trials evaluating experimental treatments or procedures
结局指标
主要结局
13CO2/12CO2 ratio
时间窗: 60 minutes
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
终止
2 期
Prediction of Severity of Liver Disease by a 13C Octanoate Breath Test (OBT)Metabolic SyndromeNonalcoholic Fatty Liver DiseaseNCT01244503Virginia Commonwealth University61
已完成
早期 1 期
13C Trioctanoate Breath Test as a Measurement of Gastric Fat Volume EmptyingHealthyNCT02602158University of Zurich32
进行中（未招募）
不适用
Gastromotal 13C-octanoic acid breath test in the diagnosis and evaluation of therapeutic outcome in patients with dyspeptic symptoms and delayed gastric emptyingPatients with dyspeptic symptoms and delayed gastric emptying.EUCTR2011-002782-38-DEINFAI GmbH60
招募中
不适用
Volatile Organic Compounds for the Assessment of Liver DiseaseCirrhosis, LiverFibrosis, LiverHepatocellular CancerHepatocellular CarcinomaCirrhosisNCT04620538Imperial College London500
终止
2 期
Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRIChronic Liver DiseaseHepatocellular Carcinoma (HCC)NCT01433016Meridian Bioscience, Inc.20